PL1732551T3 - Perheksylina do leczenia przewlekłej niewydolności serca - Google Patents
Perheksylina do leczenia przewlekłej niewydolności sercaInfo
- Publication number
- PL1732551T3 PL1732551T3 PL04768382T PL04768382T PL1732551T3 PL 1732551 T3 PL1732551 T3 PL 1732551T3 PL 04768382 T PL04768382 T PL 04768382T PL 04768382 T PL04768382 T PL 04768382T PL 1732551 T3 PL1732551 T3 PL 1732551T3
- Authority
- PL
- Poland
- Prior art keywords
- heart failure
- chronic heart
- perhexilin
- ischaemic
- treating chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0405381.5A GB0405381D0 (en) | 2004-03-10 | 2004-03-10 | A method and means for treating heart failure |
EP04768382A EP1732551B1 (en) | 2004-03-10 | 2004-09-07 | Perhexilin for treating chronic heart failure |
PCT/GB2004/003835 WO2005087233A1 (en) | 2004-03-10 | 2004-09-07 | Perhexilin for treating chronic heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1732551T3 true PL1732551T3 (pl) | 2011-05-31 |
Family
ID=32117402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04768382T PL1732551T3 (pl) | 2004-03-10 | 2004-09-07 | Perheksylina do leczenia przewlekłej niewydolności serca |
Country Status (13)
Country | Link |
---|---|
US (4) | US20070275997A1 (pl) |
EP (1) | EP1732551B1 (pl) |
JP (1) | JP5087389B2 (pl) |
CN (1) | CN1950084A (pl) |
AT (1) | ATE487480T1 (pl) |
DE (1) | DE602004030048D1 (pl) |
DK (1) | DK1732551T3 (pl) |
ES (1) | ES2358514T3 (pl) |
GB (1) | GB0405381D0 (pl) |
MX (1) | MXPA06010397A (pl) |
PL (1) | PL1732551T3 (pl) |
PT (1) | PT1732551E (pl) |
WO (1) | WO2005087233A1 (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
JP2012527438A (ja) | 2009-05-20 | 2012-11-08 | ハート メタボリクス リミテッド | 正常駆出率心不全の治療 |
US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
JP2015527375A (ja) * | 2012-09-05 | 2015-09-17 | アデレード リサーチ アンド イノベイション ピーティーワイ エルティーディーAdelaide Research & Innovation Pty Ltd | (−)−ペルヘキシリンの使用 |
CN102988347A (zh) * | 2012-11-19 | 2013-03-27 | 何晓涛 | Aphanamixoid A在制备治疗或预防慢性心衰的药物中的应用 |
GB201308736D0 (en) * | 2013-05-15 | 2013-06-26 | Univ Aberdeen | Compounds and their therapeutic use |
JP2015147787A (ja) * | 2015-04-01 | 2015-08-20 | ハート メタボリクス リミテッド | 正常駆出率心不全の治療 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN380695A0 (en) * | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
NZ550088A (en) | 2004-04-06 | 2009-08-28 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
GB0723100D0 (en) | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
JP2012527438A (ja) | 2009-05-20 | 2012-11-08 | ハート メタボリクス リミテッド | 正常駆出率心不全の治療 |
-
2004
- 2004-03-10 GB GBGB0405381.5A patent/GB0405381D0/en not_active Ceased
- 2004-09-07 EP EP04768382A patent/EP1732551B1/en not_active Expired - Lifetime
- 2004-09-07 US US10/592,250 patent/US20070275997A1/en not_active Abandoned
- 2004-09-07 AT AT04768382T patent/ATE487480T1/de active
- 2004-09-07 PT PT04768382T patent/PT1732551E/pt unknown
- 2004-09-07 JP JP2007502376A patent/JP5087389B2/ja not_active Expired - Fee Related
- 2004-09-07 CN CNA2004800429346A patent/CN1950084A/zh active Pending
- 2004-09-07 DE DE602004030048T patent/DE602004030048D1/de not_active Expired - Lifetime
- 2004-09-07 WO PCT/GB2004/003835 patent/WO2005087233A1/en active Application Filing
- 2004-09-07 PL PL04768382T patent/PL1732551T3/pl unknown
- 2004-09-07 ES ES04768382T patent/ES2358514T3/es not_active Expired - Lifetime
- 2004-09-07 MX MXPA06010397A patent/MXPA06010397A/es active IP Right Grant
- 2004-09-07 DK DK04768382.6T patent/DK1732551T3/da active
-
2011
- 2011-09-23 US US13/244,103 patent/US8470806B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/841,465 patent/US8697677B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/841,635 patent/US20130331321A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130331321A1 (en) | 2013-12-12 |
EP1732551A1 (en) | 2006-12-20 |
US20130224118A1 (en) | 2013-08-29 |
DE602004030048D1 (de) | 2010-12-23 |
DK1732551T3 (da) | 2011-02-28 |
ATE487480T1 (de) | 2010-11-15 |
GB0405381D0 (en) | 2004-04-21 |
JP2007528378A (ja) | 2007-10-11 |
CN1950084A (zh) | 2007-04-18 |
ES2358514T3 (es) | 2011-05-11 |
JP5087389B2 (ja) | 2012-12-05 |
US20070275997A1 (en) | 2007-11-29 |
US8697677B2 (en) | 2014-04-15 |
WO2005087233A1 (en) | 2005-09-22 |
US20120101128A1 (en) | 2012-04-26 |
US8470806B2 (en) | 2013-06-25 |
EP1732551B1 (en) | 2010-11-10 |
PT1732551E (pt) | 2011-02-15 |
MXPA06010397A (es) | 2007-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
MY156243A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
TW200616608A (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
HK1120441A1 (en) | Drugs for treatment of ovarian cancer | |
WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
HK1125039A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
WO2007149283A3 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
SE0400184D0 (sv) | New therapeutical use | |
MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
MX2009004051A (es) | Uso de antagonistas de il-1 para tratar gota y pseudo gota. | |
MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
EP1677806A4 (en) | METHOD FOR THE TREATMENT OF ACUTE AND HYALURONIC ACIDIFICATION CAUSED BY EXCESSIVE INJURY AND STUPIDATION | |
PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
WO2008088987B1 (en) | Treatment of pain with naloxone | |
MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
MX2024002602A (es) | Métodos para prevenir y tratar el dolor y síntomas asociados. | |
WO2005097088A3 (en) | Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure | |
MD3476F1 (en) | Method of treating the essential hypertension associated with pronounced depressions |